M7583
|
BTK inhibitor
|
R/R DLBCL, WM, MCL, MZL, SLL
|
18
|
50%
|
11%
|
Diarrhea
|
[80]
|
ME-401
|
PI3Kδ
|
R/R FL, CLL
|
31
|
83%
|
NA
|
Diarrhea, rash
|
[81]
|
LAM-002A
|
Endosomal protein inhibitor
|
R/R DLBCL, MCL, FL, MZL, CLL
|
24
|
NA
|
NA
|
Tumor lysis syndrome
|
[82]
|
INCB057643
|
BET protein inhibitor
|
R/R FL, DLBCL
|
5
|
33% (DE)
|
None
|
Hyperglycemia, thrombocytopenia, anemia, hyperbilirubinemia, Increased INR
|
[83]
|
MRG-106
|
miR-155 inhibitor
|
Mycosis fungoides
|
38
|
NA
|
NA
|
Pruritus, tumor flare
|
[84]
|
DS-3201b
|
EZH1/2 dual inhibitor
|
PTL, AITL, DLBCL, FL, MZL
|
15
|
53%
|
6.6%
|
Pneumonia
|
[85]
|
Apatinib
|
VEGFR-2 tyrosine kinase inhibitor
|
R/R NHL
|
21
|
47.6%
|
9.5%
|
None
|
[86]
|